Under construction – not a live service
Sign in
Not yet taking people in ChinaNo phase

Predicting Recovery From Advanced Cirrhosis Using Spleen Stiffness and Blood Tests

Studies whether spleen stiffness and blood tests predict recovery in adults with advanced cirrhosis.

Plain-language title generated from the registry record
Registry title: A Study to Predict Recompensation in Patients With Decompensated Cirrhosis Using Spleen Stiffness and Simple Blood Tests

Key facts

Where
Beijing, Changsha, Changzhi, Foshan, Fuzhou, Guangzhou, Guiyang, Jincheng, Jinzhong, Lanzhou, Nanchang, Nanjing, Qingdao, Shanghai, Shenyang, Shiyan, Taiyuan, and Zhuhai, ChinaSee the 28 sites

AI summary: who the study is looking for

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with decompensated cirrhosis whose liver disease cause is already under effective treatment. It will follow whether they recover and stay stable.

Age
18 to 75 years
Sex
Men and women can join.
Disease stage
Decompensated cirrhosis. The first decompensated event was within 12 months of screening, or there was none in the past 12 months despite earlier decompensation.
Earlier treatment
Must have had effective treatment of the cause: for HBV, sustained antiviral suppression; for alcohol-related disease, sustained abstinence for ≥2 months; for MAFLD-related cirrhosis, improved liver function after lifestyle or metabolic changes.

Main reasons for not taking part

  • Prior liver transplant or TIPS
  • Prior splenectomy, splenic embolization or other shunt surgery
  • Current or past liver cancer (hepatocellular carcinoma)
  • Acute variceal bleeding in the last 4 weeks or unstable condition
  • Pregnant or breastfeeding women

Read by machine on 9 November 2026.

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 75 years old?

Source: NCT07087041, who can take part

Where in China

  • Beijing Ditan Hospital, Capital Medical UniversityBeijing, ChinaNo longer taking part
  • Beijing Friendship Hospital, Capital Medical UniversityBeijing, ChinaNo longer taking part
  • Beijing You'an Hospital, Capital Medical UniversityBeijing, ChinaNo longer taking part
  • Hunan Provincial People's HospitalChangsha, ChinaNo longer taking part
  • Xiangya Hospital Central South UniversityChangsha, ChinaNo longer taking part
  • Changzhi People's HospitalChangzhi, ChinaNo longer taking part
  • Foshan Traditional Chinese Medicine HospitalFoshan, ChinaNo longer taking part
  • The First People's Hospital of FoshanFoshan, ChinaNo longer taking part
  • Mengchao Hepatobiliary Hospital of Fujian Medical UniversityFuzhou, ChinaNo longer taking part
  • The First Affiliated Hospital of Fujian Medical UniversityFuzhou, ChinaNo longer taking part
  • Guangdong Provincial Hospital of Chinese MedicineGuangzhou, ChinaNo longer taking part
  • Guangzhou Eighth People's HospitalGuangzhou, ChinaNo longer taking part
  • Nanfang Hospital, Southern Medical UniversityGuangzhou, ChinaNo longer taking part
  • Panyu Central HospitalGuangzhou, ChinaNo longer taking part
  • Guizhou Provincial People's HospitalGuiyang, ChinaNo longer taking part
  • Jincheng People's HospitalJincheng, ChinaNo longer taking part
  • Jinzhong People's HospitalJinzhong, ChinaNo longer taking part
  • The Second Hospital of Lanzhou UniversityLanzhou, ChinaNo longer taking part
  • The Second Affiliated Hospital of Nanchang UniversityNanchang, ChinaNo longer taking part
  • Nanjing Second HospitalNanjing, ChinaNo longer taking part
  • QingDao Municipal HospitalQingdao, ChinaNo longer taking part
  • Huadong Hospital, Fudan UniversityShanghai, ChinaNo longer taking part
  • Shanghai Public Health Clinical CenterShanghai, ChinaNo longer taking part
  • The First Affiliated Hospital of China Medical UniversityShenyang, ChinaNo longer taking part
  • Taihe Hospital, ShiyanShiyan, ChinaNo longer taking part
  • The First Hospital of Shanxi Medical UniversityTaiyuan, ChinaNo longer taking part
  • The Second Hospital of Shanxi Medical UniversityTaiyuan, ChinaNo longer taking part
  • The Fifth Affiliated Hospital of Sun Yat-sen University, ZhuhaiZhuhai, ChinaNo longer taking part

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Beijing Friendship Hospital
Trial code
NCT07087041
Record updated
25 July 2025
Original description
The goal of this observational study is to learn if spleen stiffness and other non-invasive markers can help predict recompensation in people with decompensated cirrhosis who are receiving effective treatment for the cause of their liver disease. The main questions it aims to answer are:Read full original descriptionShow less

Prediction of Recompensation and Stable Recompensation in Patients With Decompensated Cirrhosis Using Spleen Stiffness Combined With Non-Invasive Markers: A Prospective, Observational, Multicenter Study

The goal of this observational study is to learn if spleen stiffness and other non-invasive markers can help predict recompensation in people with decompensated cirrhosis who are receiving effective treatment for the cause of their liver disease. The main questions it aims to answer are:

* Can spleen stiffness and blood test results predict who will get better and stay better after cirrhosis becomes worse? * What are the features of people who recover after decompensation?

Participants will:

* Be people with decompensated cirrhosis who are already getting effective treatment (such as antiviral therapy or alcohol abstinence) * Be followed over time to check if they remain stable or have more liver problems * Have non-invasive tests done, including spleen stiffness measurement and blood tests

Researchers will track how many participants recover and stay recovered over time, and use that information to build a tool to help predict outcomes in others with cirrhosis.

Inclusion: Male or female, aged 18 to 75 years (inclusive); Clinically diagnosed decompensated cirrhosis; First decompensated event occurred within 12 months of screening, or no decompensated events in the past 12 months despite a history of decompensation; Received effective etiological treatment per guidelines:; For HBV: Sustained antiviral suppression; For alcohol-related liver disease: Sustained abstinence for ≥2 months; For MAFLD-related cirrhosis: Improved liver function after lifestyle/ metabolic intervention.

Exclusion: Prior orthotopic liver transplantation or TIPS; Prior splenectomy, splenic embolization, or other shunt surgery; Acute variceal bleeding within the last 4 weeks or unstable condition; Cholestatic cirrhosis; untreated chronic liver diseases; non-cirrhotic portal hypertension; vascular liver diseases (e.g., Budd-Chiari syndrome); Acute or chronic portal vein thrombosis; Severe comorbidities of heart, lung, kidney, brain, hematologic, or psychiatric systems; Other systemic malignancies (except cured cases); Missing data on first decompensated event; History or current diagnosis of hepatocellular carcinoma; Uncontrolled moderate-to-severe ascites; Pregnant or breastfeeding women.

ClinicalTrials.gov NCT07087041